CAR-Macrophage Patents

CAR-macrophage (CAR-M) patents cover engineered-macrophage/CAR-M innovations; phagocytosis/effector-function innovations; tumor-microenvironment-remodeling innovations; and iPSC-macrophage and myeloid-engineering innovations — with IP held by myeloid cell-therapy biotechs and their academic origins (in a field engineering macrophages to attack cancer). WHY CAR-MACROPHAGE THERAPY: CAR-T cell therapy transformed blood cancers but largely FAILS in SOLID tumors — CAR-T cells don't infiltrate solid tumors well and get suppressed by the tumor microenvironment; MACROPHAGES are innate immune cells that naturally INFILTRATE solid tumors, ENGULF (phagocytose) targets, present antigens, and shape immune responses — so engineering macrophages with a CHIMERIC ANTIGEN RECEPTOR (CAR) to recognize and eat tumor cells, remodel the suppressive tumor microenvironment, and recruit other immune cells directly attacks CAR-T's biggest weakness; an emerging cell-therapy frontier. MAJOR HOLDERS: CARISMA THERAPEUTICS (the CAR-M pioneer, originating from Saar Gill's lab at UPenn), MYELOID THERAPEUTICS, and emerging myeloid cell-therapy players. Engineered macrophages/CAR-M, phagocytosis/effector function, tumor-microenvironment remodeling, iPSC-derived macrophages, and myeloid engineering/delivery are the core CAR-M patent domains — and CAR-M constructs, microenvironment remodeling, iPSC sourcing, and delivery are the open whitespace.

Engineered-macrophage/CAR-M-construct innovations; phagocytosis/effector-function innovations; tumor-microenvironment-remodeling innovations; and antigen-presentation/epitope-spreading innovations represent core CAR-M patent domains — and the receptor that directs macrophages to eat tumors and their unique ability to reshape the tumor environment are the foundational, high-value capabilities. ENGINEERED-MACROPHAGE / CAR-M-CONSTRUCT PATENTS: the CAR (and the intracellular signaling domains) that directs a macrophage to recognize a tumor antigen and PHAGOCYTOSE (engulf) the tumor cell — macrophage-specific CAR designs (different signaling than CAR-T, e.g., phagocytic signaling domains) and the target antigens; the CAR-M construct/composition is core, high-value IP (a macrophage-tuned CAR is the heart of the therapy). PHAGOCYTOSIS / EFFECTOR-FUNCTION PATENTS: engineering the macrophage's killing — directed PHAGOCYTOSIS, sustained anti-tumor activity, avoiding the 'don't-eat-me' signals tumors use (e.g., CD47-SIRPα), and secondary effector functions; phagocytosis-engineering methods are high-value (eating tumor cells effectively is the core mechanism). TUMOR-MICROENVIRONMENT-REMODELING PATENTS: a KEY macrophage advantage — flipping the immunosuppressive M2-like tumor macrophages toward a pro-inflammatory M1 state, secreting cytokines, and REMODELING the suppressive tumor MICROENVIRONMENT to make tumors visible to the immune system; microenvironment-remodeling methods are distinctive, high-value IP (it's something CAR-T can't do). ANTIGEN-PRESENTATION / EPITOPE-SPREADING PATENTS: macrophages PRESENT tumor antigens to T cells, recruiting and activating a broader anti-tumor response (EPITOPE SPREADING) — extending efficacy beyond the CAR target; antigen-presentation/epitope-spreading methods are high-value (a unique, durable mechanism). CAR-M constructs, phagocytosis, microenvironment remodeling, and antigen presentation are the highest-value core IP because directing macrophages to eat tumors, reshape the microenvironment, and recruit broader immunity is exactly what gives CAR-M its solid-tumor edge.

iPSC-derived-macrophage innovations; myeloid-engineering/delivery innovations; in-vivo-reprogramming innovations; and persistence and manufacturing innovations represent additional CAR-M patent domains — and sourcing renewable macrophages, getting genes into them, and engineering them inside the body are where CAR-M's practical hurdles (and high-value IP) lie. iPSC-DERIVED-MACROPHAGE PATENTS: macrophages are hard to EXPAND from a patient's blood (they don't proliferate like T cells), so deriving them from INDUCED PLURIPOTENT STEM CELLS (iPSCs) gives a renewable, consistent, OFF-THE-SHELF (allogeneic) macrophage source; iPSC-macrophage differentiation/engineering methods are distinctive, high-value IP (it solves the supply/scalability problem and enables off-the-shelf products). MYELOID-ENGINEERING / DELIVERY PATENTS: macrophages strongly RESIST viral transduction (they're designed to destroy viruses), so getting the CAR gene IN is hard — specialized viral vectors (e.g., chimeric/Ad5f35 adenovirus), non-viral methods, and myeloid-specific engineering are core, high-value IP (delivery is a major technical barrier unique to myeloid cells). IN-VIVO-REPROGRAMMING PATENTS: rather than engineering cells ex vivo, directly reprogramming macrophages INSIDE the body (e.g., via mRNA/LNP targeting myeloid cells — Myeloid Therapeutics' approach) — an off-the-shelf, scalable alternative; in-vivo myeloid-reprogramming methods are distinctive, high-value whitespace. PERSISTENCE / MANUFACTURING PATENTS: macrophage persistence/fitness in the tumor and manufacturing/scale-up; persistence and manufacturing methods are valuable. iPSC macrophages, myeloid delivery, in-vivo reprogramming, and manufacturing are the highest-value enabling IP because solving macrophage sourcing, transduction, and (potentially) in-vivo engineering is exactly what makes CAR-M practical and scalable.

CAR-macrophage startup IP strategy must navigate Carisma's foundational CAR-M portfolio (UPenn/Saar Gill origin — the pioneering CAR-M patents), Myeloid Therapeutics' in-vivo approach, the CAR-T/cell-therapy IP overlap (CAR constructs, vectors, and manufacturing partly shared — and CAR-T's foundational IP may touch CAR-M), the myeloid-delivery problem (macrophages resist transduction — a key technical and IP area), the iPSC-vs-blood-vs-in-vivo sourcing split, the solid-tumor-efficacy bar (CAR-M's whole rationale — clinical proof in solid tumors is the make-or-break), the heavy clinical/FDA path, and a landscape where CAR-M constructs, microenvironment remodeling, iPSC macrophages, delivery, and in-vivo reprogramming are the durable assets; understand that Carisma holds foundational CAR-M IP, so the durable IP for newcomers is in novel CAR-M constructs/targets, macrophage-specific engineering (phagocytosis/signaling), microenvironment remodeling, iPSC sourcing, myeloid delivery, and in-vivo reprogramming — with delivery/engineering know-how and clinical solid-tumor data often the real moat, and that solid-tumor efficacy, delivery, manufacturability, and FTO matter as much as patents; identify whitespace in in-vivo reprogramming, iPSC macrophages, and delivery. CAR-M STARTUP IP STRATEGY: NOVEL CAR-M CONSTRUCTS/TARGETS, MACROPHAGE ENGINEERING, MICROENVIRONMENT REMODELING, iPSC SOURCING, DELIVERY, AND IN-VIVO REPROGRAMMING ARE THE IP: patent novel CAR-M constructs/targets, phagocytosis/signaling engineering, microenvironment-remodeling, iPSC-macrophage methods, myeloid delivery, and in-vivo reprogramming; CHECK CARISMA (UPenn/GILL) FOUNDATIONAL CAR-M IP + CAR-T OVERLAP: the pioneering CAR-M patents (and foundational CAR/cell-therapy IP) are key — analyze FTO and differentiate; SOLID-TUMOR EFFICACY IS THE WHOLE RATIONALE: CAR-M exists because CAR-T fails in solid tumors — clinical proof of solid-tumor efficacy is the make-or-break (and many cell therapies have struggled here); MYELOID DELIVERY IS A KEY TECHNICAL BARRIER AND IP AREA: macrophages resist viral transduction — specialized vectors/non-viral/in-vivo delivery methods are high-value, distinctive IP; MICROENVIRONMENT REMODELING + EPITOPE SPREADING ARE CAR-M's UNIQUE ADVANTAGES: flipping suppressive macrophages and recruiting broader immunity are things CAR-T can't do — high-value, defensible mechanism IP; iPSC MACROPHAGES SOLVE SOURCING (OFF-THE-SHELF): renewable iPSC-derived macrophages enable allogeneic, scalable products (macrophages don't expand from blood) — distinctive IP; IN-VIVO REPROGRAMMING IS HIGH-VALUE WHITESPACE: directly reprogramming myeloid cells in the body (mRNA/LNP — Myeloid Therapeutics) is a scalable, off-the-shelf alternative — distinctive IP; SOLID-TUMOR-EFFICACY/DELIVERY/MANUFACTURABILITY/FTO MATTER AS MUCH AS PATENTS: clinical efficacy, delivery, scalable manufacturing, and freedom-to-operate drive value; WHEN TO PATENT: NOVEL CONSTRUCT/REMODELING/iPSC/DELIVERY/IN-VIVO WITH MEASURED DATA: file once a candidate shows measured results (tumor phagocytosis/killing + microenvironment remodeling + tumor infiltration + delivery/transduction efficiency + solid-tumor efficacy) — measured solid-tumor killing/infiltration, microenvironment remodeling, and delivery efficiency are the critical CAR-M IP metrics; KEY FTO CHECKLIST: Carisma (UPenn/Gill) foundational CAR-M; Myeloid Therapeutics in-vivo; CAR-T/cell-therapy foundational + vector/manufacturing overlap; CAR-M construct (macrophage-tuned CAR/phagocytic signaling)/target; phagocytosis/effector (CD47-SIRPα 'don't-eat-me')/effector function; tumor-microenvironment remodeling (M2→M1)/cytokines; antigen presentation/epitope spreading; iPSC-derived macrophage differentiation/engineering; myeloid delivery (Ad5f35/chimeric vectors/non-viral); in-vivo reprogramming (mRNA/LNP myeloid-targeting); persistence/manufacturing; FDA/clinical path.